The Cigna Group
CI
$290.05
+3.31%
The Cigna Group is a diversified healthcare enterprise operating two primary segments: Evernorth, its pharmacy benefit management and specialty pharmacy platform, and Cigna Healthcare, its employer-focused health insurance and benefits business. The company is a dominant player in the PBM space, with its Express Scripts acquisition creating a scale platform that serves health plans, employers, and government programs, including its largest contract with the Department of Defense and a multiyear deal with Centene. The current investor narrative centers on Cigna's strategic pivot away from non-core assets, including its exit from the individual exchange business and a strategic review of eviCore, alongside raised full-year guidance that signals confidence in its core PBM and employer-benefits franchises. Debate is intensifying over whether this simplification strategy can offset persistent reimbursement pressures and regulatory scrutiny facing the broader managed-care and PBM industry, with recent analyst actions showing a mix of conviction and caution.…
CI
The Cigna Group
$290.05
Related headlines
Investment Opinion: Should I buy CI Today?
Rating: Buy. Cigna offers a compelling value proposition at 8.38x forward earnings with a 20.9% upside to the analyst average target of $339.36, supported by a 'buy' consensus from 25 analysts. The core thesis is that the market is overly pessimistic about PBM regulatory risk and is undervaluing Cigna's stable cash flows and strategic simplification.
Supporting evidence includes: (1) forward PE of 8.38x versus a healthcare sector average of 15-25x, a 44-66% discount; (2) revenue growth of 4.57% year-over-year in Q1 2026, with a generally upward sequential trend; (3) improving net margin at 2.17%, up from 2.02% a year ago; (4) $7.66 billion in trailing free cash flow supporting a 2.20% dividend yield with a conservative 27.04% payout ratio; and (5) a PEG ratio of 0.15, suggesting the stock is undervalued relative to expected growth. The low beta of 0.317 adds defensive appeal.
Key risks that could invalidate the thesis include: (1) accelerated PBM regulation that compresses Evernorth margins; (2) loss of a major contract such as the DoD or Centene deals; and (3) failure of the strategic pivot to offset reimbursement pressures. The rating would upgrade to Strong Buy if forward EPS estimates are raised above $48 or if the stock breaks above $315.47 on volume. It would downgrade to Hold if revenue growth decelerates below 3% or if net margin falls below 1.8%. Relative to its own history and peers, CI appears undervalued, trading near the low end of its historical PE and PB bands.
Sign up to view all
CI 12-Month Price Forecast
Cigna presents a compelling value opportunity with a forward PE of 8.38x that appears to over-discount regulatory and reimbursement risks. The company's $7.66 billion in trailing free cash flow and improving net margin support a sustainable 2.20% dividend, while the analyst consensus target of $339.36 offers 20.9% upside. The low beta of 0.317 makes it an attractive defensive holding, though its 24.43 percentage point underperformance versus the S&P 500 over the past year highlights persistent market skepticism. I would upgrade to high confidence if Q2 2026 earnings show net margin above 2.3% and revenue growth above 5%, or if the eviCore review concludes with a value-accretive sale. I would downgrade to neutral if net margin falls below 2.0% or if a major contract is lost.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cigna Group's 12-month outlook, with a consensus price target around $339.36 and implied upside of +17.0% versus the current price.
Average Target
$339.36
0 analysts
Implied Upside
+17.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$290 - $400
Analyst target range
Cigna is covered by 25 analysts, with a consensus recommendation of 'buy' and a recommendation mean of 1.72 on a scale where 1 is a strong buy and 5 is a strong sell. The average target price of $339.36 implies a substantial upside of approximately 20.9% from the current price of $280.76, indicating that the analyst community sees meaningful value in the stock. The consensus leans bullish, supported by recent institutional actions such as Bernstein maintaining an Outperform rating on July 9, 2026, and Mizuho reiterating Outperform on June 8, 2026, though some caution is evident with Barclays downgrading to Equal Weight from Overweight on May 26, 2026, and Deutsche Bank moving to Hold from Buy on May 20, 2026. The target price range spans from a low of $290.00 to a high of $400.00, a spread of $110.00 or approximately 38% of the low target, which signals moderate uncertainty among analysts. The high target of $400.00 would require a PE multiple expansion to roughly 8.6x forward earnings if EPS estimates of $46.36 are met, or it could assume accelerating growth from new PBM contracts and successful execution of the strategic pivot. The low target of $290.00, which is still above the current price, suggests that even the most conservative analysts see limited downside and price in stable margins and modest growth. The estimated revenue average of $358.21 billion for the forward period, with a range of $348.85 billion to $366.05 billion, implies low-to-mid single-digit growth, consistent with the company's recent trajectory. The tight clustering of targets above the current price, combined with the low beta and defensive characteristics, suggests that analysts view Cigna as a value play with limited downside risk, though the mixed recent rating actions indicate that conviction is not uniform across the Street.
Drowning in data?
Find the real signal!
Bulls vs Bears: CI Investment Factors
The bear case currently has stronger near-term evidence, given CI's 24.43 percentage point underperformance versus the S&P 500 over the past year and its thin 2.17% net margin. However, the bull case rests on a compelling valuation disconnect: a forward PE of 8.38x and a PEG of 0.15 suggest the market is pricing in severe pessimism that may not materialize. The single most important tension is whether Cigna's strategic pivot—exiting individual exchanges and reviewing eviCore—can stabilize margins and restore earnings growth, or whether PBM regulatory pressure will further compress profitability. If forward EPS estimates of $46.36 prove achievable, the stock is deeply undervalued; if they are revised down, the low multiple is justified. Analyst consensus leans bullish with a $339.36 average target, but recent downgrades show conviction is not uniform.
Bullish
- Deep value on forward earnings: CI trades at a forward PE of 8.38x versus a trailing PE of 12.34x, implying the market expects EPS to more than double to $46.36. This is a steep discount to the healthcare sector's typical 15-25x range and sits in the lower half of CI's own historical PE band of 7.65x-32.68x.
- Analyst consensus sees 20.9% upside: 25 analysts rate CI a 'buy' with a mean recommendation of 1.72 and an average target of $339.36, implying 20.9% upside from $280.76. Even the lowest target of $290.00 is above the current price, suggesting limited downside in the most conservative scenario.
- Defensive low-beta profile: CI's beta of 0.317 makes it roughly 68% less volatile than the broader market, offering portfolio stability. Its 2.20% dividend yield and 27.04% payout ratio provide income with ample room for growth, supported by $7.66 billion in trailing free cash flow.
- Improving profitability and cash generation: Q1 2026 net margin rose to 2.17% from 2.02% a year earlier, with net income of $1.65 billion. Gross margin improved to 9.45% from 7.66% in Q4 2025, and ROE of 14.28% demonstrates solid capital efficiency.
Bearish
- Persistent underperformance versus market: CI has declined 8.21% over the past year while the S&P 500 gained 16.22%, a relative underperformance of 24.43 percentage points. The 3-month change of -5.79% and YTD gain of just 0.59% show the stock continues to lag despite a recent bounce.
- Thin margins leave little error room: Net margin of 2.17% and operating margin of 3.32% mean small cost or reimbursement changes can significantly impact earnings. Gross margin has been volatile, ranging from 7.66% in Q4 2025 to 11.73% in Q2 2025, highlighting earnings unpredictability.
- Regulatory and reimbursement headwinds: The PBM industry faces persistent reimbursement pressures and regulatory scrutiny, as noted in recent sector news. Cigna's heavy reliance on Evernorth, which generated $58.44 billion of $68.49 billion in Q1 2026 revenue, makes it especially vulnerable to PBM-specific regulation.
- Mixed analyst conviction and downgrades: Despite a 'buy' consensus, Barclays downgraded CI to Equal Weight on May 26, 2026, and Deutsche Bank moved to Hold on May 20, 2026. The target range of $290-$400 spans 38% of the low target, signaling meaningful disagreement about execution.
CI Technical Analysis
Cigna is in a recovery phase within a broader range-bound structure, with the current price of $280.76 sitting at approximately 54.3% of its 52-week range between a low of $239.51 and a high of $315.47. The 1-year price change of -8.21% reflects a year of underperformance, but the stock has clawed back from its lows, suggesting that selling pressure has exhausted and a base is forming. This positioning is neither overextended nor deeply discounted, implying the market is in a wait-and-see mode regarding the company's strategic pivot and earnings trajectory. Recent momentum has turned constructive, with a 1-month gain of 1.21% contrasting sharply with the 3-month decline of -5.79% and the 1-year loss of -8.21%. This divergence signals a potential trend reversal, as the short-term bounce is attempting to offset the intermediate downtrend. The 6-month change of +5.08% and YTD gain of 0.59% further support the view that the stock is stabilizing, though the 1-month relative strength of +2.27% against SPY indicates only modest outperformance. The stock's beta of 0.317 is remarkably low, meaning it is roughly 68% less volatile than the broader market, which makes it a defensive holding but also limits upside torque in a rally. Key technical resistance lies at the 52-week high of $315.47, and a breakout above that level would signal a full trend reversal and likely attract momentum capital. Support is anchored at the 52-week low of $239.51, and a breakdown below that level would confirm a resumption of the downtrend and potentially trigger further selling. The max drawdown of -21.41% over the past year highlights the stock's vulnerability to sharp reversals despite its low beta, underscoring the importance of position sizing and stop-loss discipline.
Beta
0.32
0.32x market volatility
Max Drawdown
-21.4%
Largest decline past year
52-Week Range
$240-$315
Price range past year
Annual Return
-4.2%
Cumulative gain past year
| Period | CI Return | S&P 500 |
|---|---|---|
| 1m | +2.7% | -2.0% |
| 3m | -0.6% | +1.4% |
| 6m | +9.6% | +15.0% |
| 1y | -4.2% | +15.7% |
| ytd | +3.9% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CI Fundamental Analysis
Cigna's revenue trajectory remains solidly positive, with Q1 2026 revenue of $68.49 billion representing a 4.57% year-over-year increase from $65.50 billion in Q1 2025. The sequential trend shows revenue rising from $65.50 billion in Q1 2025 to $67.23 billion in Q2, $69.75 billion in Q3, $72.47 billion in Q4, and $68.49 billion in Q1 2026, indicating a generally upward path with some quarterly seasonality. Evernorth dominates the revenue mix at $58.44 billion, dwarfing Cigna Healthcare's $11.48 billion, which means the PBM segment is the primary growth engine and any slowdown there would disproportionately impact overall results. The 4.57% growth rate is modest but steady, consistent with a mature healthcare services company, and suggests the investment case rests more on margin expansion and capital return than on explosive top-line acceleration. Profitability is thin but improving, with Q1 2026 net income of $1.65 billion and a net margin of 2.17%, up from 2.02% in Q1 2025 and 1.70% in Q4 2025. Gross margin stands at 9.45%, which is typical for a PBM-heavy business where drug costs flow through revenue at near-cost, and the operating margin of 3.32% reflects the low-margin, high-volume nature of the model. The Q1 2026 gross margin of 9.45% compares favorably to Q4 2025's 7.66% but is below Q2 2025's 11.73%, indicating some quarterly volatility, though the net income ratio of 2.41% is the highest in the past five quarters, signaling improving bottom-line efficiency. The balance sheet shows a debt-to-equity ratio of 0.75, which is moderate for a large-cap healthcare company and provides financial flexibility without excessive leverage. Free cash flow on a trailing twelve-month basis is $7.66 billion, and the Q1 2026 free cash flow of $864 million, while lower than the Q4 2025 figure of $5.83 billion due to working capital seasonality, demonstrates the company's ability to generate cash. ROE of 14.28% and ROA of 4.46% indicate reasonable capital efficiency, and the current ratio of 0.85, while below 1.0, is typical for a company that operates with negative working capital due to rapid receivables collection and payables management. The dividend yield of 2.20% and payout ratio of 27.04% suggest a sustainable capital return policy with room for growth.
Quarterly Revenue
$68.5B
2026-03
Revenue YoY Growth
+4.6%
YoY Comparison
Gross Margin
9.4%
Latest Quarter
Free Cash Flow
$7.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CI Overvalued?
With net income positive at $1.65 billion in Q1 2026, the PE ratio is the appropriate primary valuation metric, and Cigna trades at a trailing PE of 12.34x versus a forward PE of 8.38x. The substantial gap between trailing and forward multiples implies the market expects significant earnings growth, with forward EPS estimates of $46.36 suggesting a sharp increase from the trailing EPS of $0.08, though this trailing figure appears distorted by quarterly timing or one-time items. The forward PE of 8.38x is remarkably low in absolute terms and signals that the market is pricing in either substantial earnings acceleration or significant risks that could impair future profitability. Compared to the broader healthcare sector, where PE ratios often range from 15x to 25x, Cigna's trailing PE of 12.34x represents a discount of roughly 18% to 50%, and its forward PE of 8.38x is even more deeply discounted. The PS ratio of 0.27 and EV/Sales of 0.35 are extremely low, reflecting the low-margin nature of the PBM business, but the EV/EBITDA of 8.36x is more moderate and suggests the company is not expensive on a cash-flow basis. The PEG ratio of 0.15 is exceptionally low, implying that the stock is undervalued relative to its expected growth rate, though this metric can be misleading for companies with volatile earnings. Historically, Cigna's PE ratio has ranged from a low of 7.65x in Q3 2022 to a high of 32.68x in Q3 2024, with the current 12.34x sitting in the lower half of that range. The PB ratio of 1.75 is near the lower end of its historical band, which has ranged from 1.41 to 2.53 over the past five years, suggesting the stock is trading closer to its book value floor than its ceiling. This historical context implies that either the market is pricing in pessimistic expectations about future returns on equity, or the stock presents a value opportunity if the company can sustain its current profitability trajectory.
PE
12.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.4x
Enterprise Value Multiple
Investment Risk Disclosure
Cigna's financial risk profile is dominated by its thin margins and moderate leverage. With a net margin of just 2.17% and operating margin of 3.32%, a mere 100 basis point increase in drug costs or a 1% reduction in reimbursement rates could wipe out a substantial portion of net income. The debt-to-equity ratio of 0.75 and current ratio of 0.85 indicate limited short-term liquidity cushion, though $7.66 billion in trailing free cash flow provides coverage. Revenue concentration is a key vulnerability: Evernorth generated $58.44 billion of $68.49 billion in Q1 2026 revenue, meaning any contract loss—such as the DoD or Centene deals—would disproportionately impact results.
Market and competitive risks center on valuation compression and regulatory intervention. CI's forward PE of 8.38x is already deeply discounted, but if PBM regulation intensifies or reimbursement pressures accelerate, the multiple could contract further toward its historical low of 7.65x. The stock's beta of 0.317 offers defensive characteristics but also limits upside participation in rallies, as seen in its 24.43 percentage point underperformance versus the S&P 500 over the past year. Recent news highlights persistent reimbursement pressures and regulatory challenges across the managed-care sector, and Cigna's strategic pivot introduces execution risk that could distract management from core operations.
The worst-case scenario involves a combination of regulatory action against PBM practices, loss of a major contract, and margin compression below 2%. In this scenario, CI could retest its 52-week low of $239.51, representing a 14.7% decline from the current price of $280.76. If analyst bear-case targets are revised downward—the current low target is $290.00—a more severe selloff could push the stock toward $220-$240, implying a 15-21% loss. The max drawdown of -21.41% over the past year shows the stock is capable of sharp reversals despite its low beta, underscoring the importance of position sizing and stop-loss discipline.
FAQ
The most severe risk is regulatory intervention in PBM pricing, which could compress Evernorth's margins—Evernorth accounts for $58.44 billion of $68.49 billion in quarterly revenue. Second is contract concentration risk, as the loss of the DoD or Centene deals would materially impact results. Third is margin fragility: a net margin of just 2.17% means small cost increases can significantly reduce earnings. Fourth is competitive pressure from rivals like CVS and UnitedHealth's Optum, which could erode Cigna's market share and pricing power. These risks are ranked from most to least severe based on potential earnings impact.
The 12-month forecast includes a base case (50% probability) targeting $300-$340, a bull case (30%) targeting $340-$400, and a bear case (20%) targeting $240-$290. The base case assumes revenue growth of 4-5% and stable net margins around 2.2%, aligning with the analyst average target of $339.36. The bull case requires successful execution of the strategic pivot and regulatory clarity, while the bear case reflects intensified PBM regulation and margin compression. The most likely scenario is the base case, with the key assumption being that forward EPS of $46.36 is achieved within 5%.
CI appears undervalued on multiple metrics. Its forward PE of 8.38x is well below the healthcare sector's typical 15-25x range and sits in the lower half of its own historical band of 7.65x-32.68x. The PS ratio of 0.27 and EV/EBITDA of 8.36x are also low, while the PEG ratio of 0.15 suggests the stock is cheap relative to expected growth. The market is pricing in significant pessimism about PBM regulation and margin sustainability, which may be overdone given the company's $7.66 billion in free cash flow and stable revenue base.
From a risk/reward perspective, CI offers a favorable setup with 20.9% upside to the analyst average target of $339.36 against a 14.7% downside to the 52-week low of $239.51. The forward PE of 8.38x is deeply discounted, and the 2.20% dividend yield provides income while waiting for a re-rating. However, the stock has underperformed the S&P 500 by 24.43 percentage points over the past year, and regulatory risks to the PBM model are real. It is a good buy for value-oriented, patient investors who can tolerate sector-specific regulatory uncertainty, but less suitable for those seeking high growth or momentum.
CI is better suited for long-term investment given its low beta of 0.317, 2.20% dividend yield, and deep-value valuation that may take time to re-rate. The stock's 24.43 percentage point underperformance versus the S&P 500 over the past year suggests near-term momentum is weak, and the strategic pivot will take several quarters to fully execute. Short-term traders may find limited volatility for momentum plays, though the low beta means less downside risk. A minimum holding period of 12-18 months is recommended to allow the value thesis to materialize and for regulatory uncertainties to resolve.
